Nasdaq IPOs

In the midst of the bear market for equities and the shuttered economy due to the coronavirus, venture capitalists have announced raising record amounts of money for biotechnology investments. This is a strong indication that development of novel therapies is gaining momentum and

In the midst of the bear market for equities and the shuttered economy due to the coronavirus, venture capitalists have announced raising record amounts of money for biotechnology investments. This is a strong indication that development of novel therapies is gaining momentum and

Nasdaq’s Head of Healthcare Listings on the State of IPOs During the Coronavirus Pandemic

Zentalis Pharmaceuticals, a Phase 1/2 biotech developing novel small molecule therapies for various cancers, raised $165 million in an upsized IPO by offering 9.2 million shares at $18, the high end of the range of $16 to $18. The company originally planned to sell 7.7 million sh

Renaissance Capital is releasing a preview of our 2019 pre-IPO report on Zoom Video Communications (ZM), normally only available to institutional clients of the IPO Intelligence research portal. The teleconferencing app's usage has exploded during the coronavirus crisis

2020 IPO Boom Stopped Cold by Coronavirus Meltdown The 2020 IPO market began with optimism and ended with the worst crash since the global financial crisis. 25 IPOs raised $6.8 billion, with as many as 20 companies forced to shelve offerings when the IPO window slammed shut in ea

2020 IPO Boom Stopped Cold by Coronavirus Meltdown The 2020 IPO market began with optimism and ended with the worst crash since the global financial crisis. 25 IPOs raised $6.8 billion, with as many as 20 companies forced to shelve offerings when the IPO window slammed shut in ea

Rare disease biotech Imara (IMRA) has traded in a surprisingly tight range since its March IPO, even as the biotech industry sees drastic price swings. Post-IPO filings may reveal why: Existing shareholders took down a significant portion of the deal. While Imara’s prospect

WiMi Hologram Cloud, a Chinese provider of holographic augmented reality software for advertising, raised $26 million by offering 4.8 million ADSs at $5.50, the low end of the range of $5.50 to $7.50, to command a market value of $325 million. The company had recently increased i

Keros Therapeutics, a Phase 1 biotech developing therapies for blood and musculoskeletal disorders, announced terms for its IPO on Wednesday. The Lexington, MA-based company plans to raise $75 million by offering 5 million shares at a price range of $14 to $16. At the midpoint of

Keros Therapeutics, a Phase 1/2 biotech developing therapies for blood and musculoskeletal disorders, announced terms for its IPO on Wednesday. The Lexington, MA-based company plans to raise $75 million by offering 5 million shares at a price range of $14 to $16. At the midpoint

Harbor Custom Development, a real estate developer in the Puget Sound region of Washington, filed on Tuesday with the SEC to raise up to $15 million in an initial public offering. The Gig Harbor, WA-based company was founded in 2014 and booked $31 million in revenue for the 12 mo

Of the 24 IPOs in the first quarter of 2020, eight were backed by private equity firms. These deals raised $4.6 billion, a $4.3 billion jump in proceeds from the 1Q19. The financial sector led PE-backed activity with three IPOs, with additional activity from health

Of the 24 IPOs in the 1Q20, venture capital brought 12 deals to market that raised $1.9 billion. Healthcare drove venture exits in the quarter, producing nine IPOs, but the absence of tech unicorns weighed on venture activity. The quarter's most active venture firm New Enterprise

Of the 24 IPOs in the 1Q20, venture capital brought 12 deals to market that raised $1.9 billion. Healthcare drove venture exits in the quarter, producing nine IPOs, but the absence of tech unicorns weighed on venture activity. The quarter's most active venture firm New Enterprise

Of the 24 IPOs in the 1Q20, venture capital brought 12 deals to market that raised $1.9 billion. Healthcare drove venture exits in the quarter, producing nine IPOs, but the absence of tech unicorns weighed on venture activity. The quarter’s most active ventur

Zentalis Pharmaceuticals, a Phase 1/2 biotech developing novel small molecule therapies for various cancers, announced terms for its IPO on Monday. The New York, NY-based company plans to raise $130 million by offering 7.7 million shares at a price range of $16 to $18. At the mid

Zentalis Pharmaceuticals, a Phase 1/2 biotech developing novel small molecule therapies for various cancers, announced terms for its IPO on Monday. The New York, NY-based company plans to raise $130 million by offering 7.7 million shares at a price range of $16 to $18. At the mid

Zentalis Pharmaceuticals, a Phase 1/2 biotech developing novel small molecule therapies for various cancers, announced terms for its IPO on Monday. The New York, NY-based company plans to raise $130 million by offering 7.7 million shares at a price range of $16 to $18. At the mid

2020 IPO Boom Stopped Cold by Coronavirus Meltdown The 2020 IPO market began with optimism and ended with the worst crash since the global financial crisis. 24 IPOs raised $6.8 billion, with as many as 20 companies forced to shelve offerings when the IPO window slammed shut in ea